

Special Issue

Clinical Significance of cfRNAs as Tumor Biomarkers

Message from the Guest Editor

The investigation of cfRNA in plasma to monitor disease is a rapidly growing area of diagnostic research.

Increasing evidence shows that long RNA species, including messenger RNA (mRNA), circular RNA (circRNA), and long noncoding RNAs (lncRNA), are also found in human blood and have functional and clinical implications. The Special Issue aims to advance the emerging standpoint on the importance of holistic knowledge of cfRNA as a tumor biomarker. Therefore, authors are invited to submit original research and review papers that are focused on, but not limited to, the following topics:

- The clinical scope of cfRNA as a biomarker;
- Preanalytical optimization, standardization, and quality control;
- Exciting applications of cfRNA analysis in oncology;
- The use of cfRNA as a tool for early cancer detection;
- Monitoring minimal residual disease in cancer by using cfRNA biomarkers;
- Comparative analysis of methods and technologies for the detection of cfRNA;
- Enrichment strategies for circulating tumor cfRNA (extraction methods);
- The use of RNA sequencing (RNA-seq) to investigate the vast diversity of RNA species.

Guest Editor

Dr. Athina N. Markou

Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

Deadline for manuscript submissions

closed (15 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/164577

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)